The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 524K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diehl, N. L.
Right arrow Articles by Rincón, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diehl, N. L.
Right arrow Articles by Rincón, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/2000/1/321/ $5.00
The Journal of Experimental Medicine, Volume 191, Number 2, January 17, 2000 321-334


Original Article

Activation of the p38 Mitogen-Activated Protein Kinase Pathway Arrests Cell Cycle Progression and Differentiation of Immature Thymocytes in Vivo

Nicole L. Diehla, Hervé Enslenb,c, Karen A. Fortnera, Chris Merritta, Nate Stetsona, Colette Charlanda, Richard A. Flavelld,e, Roger J. Davisb,c, and Mercedes Rincóna

a Immunobiology Program, Department of Medicine, University of Vermont, Burlington, Vermont 05405
b Program in Molecular Medicine, Department of Biochemistry and Molecular Biology, University of Massachusetts Medical School,
c Howard Hughes Medical Institute, Worcester, Massachusetts 01605
d Section of Immunobiology, Yale University School of Medicine,
e Howard Hughes Medical Institute, New Haven Connecticut 06520
Immunobiology Program, Department of Medicine, Given Medical Building D-305, University of Vermont, Burlington, VT 05405.802-656-3854802-656-0937

mrincon{at}zoo.uvm.edu

The development of T cells in the thymus is coordinated by cell-specific gene expression programs that involve multiple transcription factors and signaling pathways. Here, we show that the p38 mitogen-activated protein (MAP) kinase signaling pathway is strictly regulated during the differentiation of CD4CD8 thymocytes. Persistent activation of p38 MAP kinase blocks fetal thymocyte development at the CD25+CD44 stage in vivo, and results in the lack of T cells in the peripheral immune system of adult mice. Inactivation of p38 MAP kinase is required for further differentiation of these cells into CD4+CD8+ thymocytes. The arrest of cell cycle in mitosis is partially responsible for the blockade of differentiation. Therefore, the p38 MAP kinase pathway is a critical regulatory element of differentiation and proliferation during the early stages of in vivo thymocyte development.

Key Words: transgenic mice • thymocyte development • mitosis • apoptosis • T cells


N.L. Diehl and H. Enslen contributed equally to this paper.

Abbreviations used in this paper: BrdU, bromodeoxyuridine; DN, double negative; DP, double positive; ERK, extracellular signal regulatory kinase; FTOC, fetal thymocyte development organ culture; GST, glutathione S-transferase; JNK, c-Jun NH2-terminal kinase; HSA, heat stable antigen; MAP, mitogen-activated kinase; MKK, MAP kinase kinase; RAG, recombination activating gene; TUNEL, terminal deoxynucleotidyl transferase–mediated FITC-dUTP nick end labeling.

© 2000 The Rockefeller University Press


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS